Amplisynth Ltd. has secured $400,000 in a recent funding round, the company announced today. This capital injection marks a significant milestone for the firm, which specializes in advanced DNA printing technology designed to democratize access to synthetic DNA for scientific research.
The company's core offering focuses on same-day, long-length DNA synthesis, providing a decentralized and kitless solution for laboratories. Amplisynth emphasizes a fully automated process with ultra-low skill requirements, making complex genetic material more accessible. Its open-source framework is engineered for seamless integration into existing laboratory pipelines, aiming to grant researchers greater autonomy over their synthetic DNA needs. The company was founded on the belief that the potential of DNA is too vital to be treated merely as a reagent, advocating for greater control and immediate access.
This funding will be strategically deployed to accelerate Amplisynth's product development and expand its operational capabilities. The investment is earmarked for further enhancing its proprietary automated DNA synthesis platform and supporting the ongoing research and development initiatives critical for scaling its technology. This financial backing underscores investor confidence in Amplisynth’s innovative approach to addressing critical bottlenecks in genetic research and biotechnology.
Looking ahead, Amplisynth Ltd. aims to solidify its position as a leader in autonomous, immediate DNA synthesis. The company plans to leverage this new capital to broaden its market reach and foster widespread adoption of its technology, ultimately empowering scientific discovery across various disciplines by transforming how laboratories acquire and utilize synthetic DNA.
